Budesonide

Overview

Budesonide is a potent corticosteroid used primarily for its anti-inflammatory properties. It is commonly used in the treatment of asthma, inflammatory bowel diseases, and allergic rhinitis.

API suppliers (25)

Suppliers of Budesonide evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• TAPI NL BVNetherlands2 active DMF
• FARMABIOS SPAItaly2 active DMF
• MINAKEMFrance1 active DMF
• NEWCHEM SPAItaly1 active DMF GMP on record
• CURIA SPAIN SAUSpain1 active DMF GMP on record
• Sun Pharmaceutical Industries LimitedIndia1 active DMF GMP on record
• Apotex Inc.Canada1 active DMF
• Cipla USA, Inc.USA1 active DMF
• TIANJIN TIANYAO PHARMACEUTICALS CO LTDChina1 active DMF
• ASTRAZENECA PHARMACEUTICAL LP1 active DMF
• Amphastar Nanjing PharmaceuticalsChina1 active DMF
• Hubei Gedian Humanwell Pharmaceutical Co. LtdChina1 active DMF GMP on record
• VAMSI LABS LTDIndia1 active DMF GMP on record
• HENAN LIHUA PHARMACEUTICAL CO LTD1 active DMF
• CHEMO IBERICA SA1 active DMF
• Aurisco Pharmaceutical Co.,ltdChina1 active DMF GMP on record
• SHANDONG RISEN-SUN PHARMACEUTICAL CO LTD1 active DMF
• CORAL DRUGS PRIVATE LTD1 active DMF GMP on record
• INDUSTRIALE CHIMICA SRLItaly1 active DMF GMP on record
• STERLING SPAItaly1 active DMF GMP on record
• ASPEN OSS BVNetherlands1 active DMF GMP on record
• AARTI PHARMALABS LIMITEDIndia1 active DMF
• SYMBIOTEC PHARMALAB LTD1 active DMF GMP on record
• FARMABIOS SRL GMP on record
• Aspen Pharmacare Holdings LimitedSouth AfricaCEP

Patent & exclusivity (US)

Per the FDA Orange Book (35 approved US products), the latest listed US patent on Budesonide expires 23 Jan 2043 and exclusivity 9 Feb 2031. Generic API sourcing typically opens up once these lapse.

Therapeutic areas